GlassScriptPhysician profile
Mina Baha Essak
NPI 1477058964
$7,555.02
in general payments reported to CMS, 2019-2025
31 companies · $4,899 in 2025
The $4,899 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $138 · 2021: $270 · 2022: $365 · 2023: $508 · 2024: $1,201 · 2025: $4,899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,150 · Food and Beverage: $1,932 · Consulting Fee: $1,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,150.00 |
| Food and Beverage | $1,932.09 |
| Consulting Fee | $1,525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,915.07 | 2023-2025 | |
| Abbvie INC. | $569.80 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $211.16 | 2023-2024 | Ajovy, Austedo Xr |
| Genentech USA, INC. | $190.32 | 2019-2024 | Ocrevus, Enspryng |
| Horizon Therapeutics Plc | $186.85 | 2022-2023 | Uplizna |
| Biohaven Pharmaceuticals, INC. | $147.75 | 2021 | |
| Alexion Pharmaceuticals, INC. | $143.51 | 2019-2024 | Soliris, Ultomiris |
| Kyowa Kirin, INC. | $122.02 | 2021 | |
| Axsome Therapeutics, INC. | $121.03 | 2025 | Symbravo |
| Adamas Pharmaceuticals, INC. | $120.35 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $118.08 | 2022 | |
| Amgen INC. | $88.62 | 2024 | Uplizna |
| Lilly USA, LLC | $80.13 | 2024 | Amyvid, Reyvow, Emgality |
| Lundbeck LLC | $72.01 | 2023-2024 | Vyepti |
| Tg Therapeutics, INC. | $55.97 | 2023-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $49.97 | 2024 | Nuplazid |
| Eisai INC. | $47.21 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.32 | 2024 | Hyqvia |
| Biogen, INC. | $34.72 | 2023-2024 | Spinraza |
| Acorda Therapeutics, INC | $33.53 | 2019 | |
| Tanabe Pharma America, INC. | $30.45 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $23.48 | 2023 | Rexulti |
| Scilex Pharmaceuticals INC. | $20.94 | 2023 | Ztlido |
| Sk Life Science, INC. | $19.78 | 2024 | |
| Xeris Pharmaceuticals, INC. | $19.55 | 2024 | Keveyis |
| Neurelis, INC. | $18.80 | 2023 | Valtoco |
| Averitas Pharma INC. | $18.16 | 2024 | Qutenza |
| Allergan, INC. | $18.09 | 2020 | |
| Ucb, INC. | $15.38 | 2023 | Briviact |
| Hospira, INC. | $13.70 | 2024 | |
| Alnylam Pharmaceuticals INC. | $13.27 | 2023 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mina Essak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.